Jump to content
Crime Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE

The targeted protein degradation enabling technologies market, featuring a healthy pipeline{Roots}


Roots Analysis has done a detailed study on Targeted Protein Degradation Market, 2021-2030., covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 330+ page report, which features 115+ figures and 180+ tables, please visit this link

 

Key Market Insights

§  Presently, several small molecule protein degraders are being evaluated for the treatment of a wide variety of disease indications; PROTACs is the most prominent sub-class in this segment with 8+ enabling technologies

§  Most of the pipeline candidates are in the early phases of development, and predominantly designed to target diverse types of cancers; majority of the drug candidates are designed for administration via non-invasive routes

§  Majority of the stakeholders in this competitive market are small firms, primarily headquartered in the US and European regions

§  Although start-ups and mid-sized firms are spearheading the innovation in this domain, many big pharmaceutical companies have also undertaken diverse initiatives related to protein degrader-based therapies

§  Over time, more than 14,500 patents related to target protein degradation technologies have been filed / granted to various industry and non-industry players, indicating the rising level of R&D activity in this field

§  Several organizations have extended financial support to aid research efforts in this domain; currently, the focus, in terms of funds disbursed, is primarily to support investigation of drugs intended for treating cancer

§  Foreseeing a lucrative future, private and public investors have invested over USD 5 billion, across 130+ instances, into firms involved in the development of protein degrader therapies

§  Till date, more than 8,500 patients have been enrolled in clinical trials of various protein degrader-based interventions; the most advanced candidates are being developed to treat breast cancer

§  Prominent scientists / medical research professionals, who have been actively involved in clinical research related to targeted protein degraders, are presently considered key opinion leaders in this domain

§  The increasing interest in this upcoming class of therapeutics is reflected in the partnership activity worldwide; most of the recent deals were established around protein degrader-related technology platforms

§  Our proprietary deal structure model suggests that IP owners should adopt a scenario-based approach to identify the most optimum / valuable deal structure while licensing their technology

§  The short-term opportunity in this market is likely to be driven by revenues from technology licensing deals, which offer lucrative long term payout options

§  The first degrader-based therapeutic, a SERD designed to treat breast cancer, is anticipated to be launched in 2023; based on prevalent trends, the market is expected to grow at an annualized rate of 25%

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

 

Table of Contents

 

1.         PREFACE
1.1.       Scope of the Report
1.2.       Research Methodology
1.3.       Chapter Outlines


2.         EXECUTIVE SUMMARY


3.         INTRODUCTION

3.1.       Context and Background

3.2.       Protein Homeostasis

3.3.       Post Translational Protein Modifications 

3.4.       Ubiquitin and the Ubiquitin Proteasome System (UPS)

3.4.1.    Structure and Functions of Ubiquitin

3.4.2.    Overview of the UPS

3.4.2.1. Components of the UPS

3.4.2.2. Ubiquitin-based Protein Degradation Pathway

 

3.5.       Therapeutic Applications of the UPS

3.6.       Ubiquitin Enzyme Inhibitors

3.6.1.    Advantages and Challenges

 

3.7.       Overview of Targeted Protein Degradation

3.7.1.    Historical Development of Protein Degraders

3.7.2.    Types of Protein Degraders

3.7.2.1. Proteolysis Targeting Chimeras (PROTACs)

3.7.2.2. Other Chimeric Protein Targeting Molecules

3.7.2.2.1. Endosome Targeting Chimeras (ENDTACs)

3.7.2.2.2. Lysosome Targeting Chimeras (LYTACs)

3.7.2.2.3. Photochemically Targeted Chimeras (PHOTACs)

3.7.2.3. Epichaperome Inhibitors

3.7.2.4. Hydrophobic Tags

3.7.2.5. Immuno-modulatory Imide Drugs (IMiDs)

3.7.2.6. Molecular Glues

3.7.2.7. Protein Homeostatic Modulators

3.7.2.8. Selective Hormone Receptor Degraders (SHRDs)

3.7.2.9. Specific and Non-genetic IAP-dependent Protein Erasers (SNIPERs)

3.7.2.10. Specific Bromodomain and Extra-terminal Motif (BET) Inhibitors and Deubiquitinase (DUB) Inhibitors

 

3.8.       Market Growth Drivers and Roadblocks

3.9.       Recent Developments and Upcoming Trends
 

 

4.         CURRENT MARKET LANDSCAPE: TARGET PROTEIN DEGRADATION-BASED THERAPEUTICS
4.1.       Chapter Overview

4.2.       Targeted Protein Degradation-based Therapeutics: Development Pipeline

4.2.1.    Analysis by Type of Protein Degrader

4.2.2.    Analysis by Phase of Development

4.2.3.    Analysis by Therapeutic Area

4.2.4.    Analysis by Target Indication

4.2.5.    Analysis by Biological Target

4.2.6.    Analysis by Associated Ubiquitin Ligase

4.2.7.    Analysis by Type of Therapy

4.2.8.    Analysis by Route of Administration

 

4.3.       Targeted Protein Degradation-based Therapeutics: Developer Landscape

4.3.1.    Analysis by Year of Establishment

4.3.2.    Analysis by Company Size

4.3.3.    Analysis by Type of Protein Degrader

4.3.4.    Analysis by Location of Headquarters

4.3.5.    Leading Players: Analysis by Number of Drug Candidates

 

5.         CURRENT MARKET LANDSCAPE: TARGET PROTEIN DEGRADATION ENABLING TECHNOLOGIES
5.1.       Chapter Overview

5.2.       Targeted Protein Degradation Enabling Technologies: List of Research Tools / Key Technology Platforms

5.2.1.    Analysis by Type of Protein Degrader

5.2.2.    Analysis by Number of Drugs under Development

5.3.       Targeted Protein Degradation Enabling Technologies: Developer Landscape

5.3.1.    Analysis by Year of Establishment

5.3.2.    Analysis by Company Size

5.3.3.    Analysis by Location of Headquarters

 

6. COMPANY PROFILES

6.1.       Chapter Overview

6.2.       Developers with Late-stage Clinical Candidates

6.2.1.    Radius Health

6.2.1.1. Company Overview

6.2.1.2. Financial Information

6.2.1.3. Targeted Protein Degradation-based Product Portfolio

6.2.1.3.1. Elacestrant (RAD1901)

6.2.1.4. Recent Developments and Future Outlook

 

6.2.2.    Celgene

6.2.2.1. Company Overview

6.2.2.2. Financial Information

6.2.2.3. Targeted Protein Degradation-based Drug Portfolio

6.2.2.3.1. Avadomide (CC-122)

6.2.2.3.2. Iberdomide (CC-220)

6.2.2.4. Recent Developments and Future Outlook

 

6.2.3.    Sanofi Genzyme

6.2.3.1. Company Overview

6.2.3.2. Financial Information

6.2.3.3. Targeted Protein Degradation-based Drug Portfolio

6.2.3.3.1. SAR439869

6.2.3.4. Recent Developments and Future Outlook

 

6.2.4.    AstraZeneca

6.2.4.1. Company Overview

6.2.4.2. Financial Information

6.2.4.3. Targeted Protein Degradation-based Drug Portfolio

6.2.4.3.1. AZD9833

6.2.4.4. Recent Developments and Future Outlook

 

6.3.       Developers with Preclinical / Early-stage Clinical Candidates

6.3.1.    Arvinas

6.3.1.1. Company Overview

6.3.1.2. Technology Overview

6.3.1.3. Drug Portfolio

6.3.1.4. Key Developments

6.3.1.5. Recent Developments and Future Outlook

 

6.3.2.    BioTheryX

6.3.2.1. Company Overview

6.3.2.2. Drug Portfolio

6.3.2.3. Key Developments

6.3.2.4. Recent Developments and Future Outlook

 

6.3.3.    Captor Therapeutics

6.3.3.1. Company Overview

6.3.3.2. Technology Overview

6.3.3.3. Drug Portfolio

6.3.3.4. Recent Developments and Future Outlook

 

6.3.4.    C4 Therapeutics

6.3.4.1. Company overview

6.3.4.2. Technology Overview

6.3.4.3. Drug Portfolio

6.3.4.4. Key Developments

6.3.4.5. Recent Developments and Future Outlook

 

6.3.5.    Genentech

6.3.5.1. Company Overview

6.3.5.2. Drug Portfolio

6.3.5.3. Key Developments

6.3.5.4. Recent Developments and Future Outlook

 

6.3.6.    Hinova Pharmaceuticals

6.3.6.1. Company Overview

6.3.6.2. Drug Portfolio

6.3.6.3. Recent Developments and Future Outlook

 

6.3.7.    Kangpu Biopharmaceuticals

6.3.7.1. Company Overview

6.3.7.2. Drug Portfolio

6.3.7.3. Key Developments

6.3.7.4. Recent Developments and Future Outlook

 

6.3.8.    Kymera Therapeutics

6.3.8.1. Company Overview

6.3.8.2. Technology Overview

6.3.8.3. Drug Portfolio

6.3.8.4. Key Developments

6.3.8.5. Recent Developments and Future Outlook

 

6.3.9.    Mission Therapeutics

6.3.9.1. Company Overview

6.3.9.2. Technology Overview

6.3.9.3. Drug Portfolio

6.3.9.4. Key Developments

6.3.9.5. Recent Developments and Future Outlook

 

6.3.10.  Progenra

6.3.10.1. Company Overview

6.3.10.2. Technology Overview

6.3.10.3. Drug Portfolio

6.3.10.4. Recent Developments and Future Outlook

 

6.3.11.  Zenopharm

6.3.16.3. Company Overview

6.3.11.2. Drug Portfolio

6.3.11.3. Recent Developments and Future Outlook       

 

7.         CLINICAL TRIAL ANALYSIS

7.1.       Chapter Overview

7.2.       Scope and Methodology

7.3.       Targeted Protein Degradation-based Therapeutics and Technologies: List of Clinical Trials

7.3.1.    Analysis by Trial Registration Year

7.3.2.    Geographical Analysis by Number of Clinical Trials

7.3.3.    Geographical Analysis by Enrolled Patient Population

7.3.4.    Analysis by Type of Protein Degrader

7.3.5.    Analysis by Trial Phase

7.3.6.    Analysis by Study Design

7.3.7.    Analysis by Type of Sponsor / Collaborator

7.3.8.    Most Active Players: Analysis by Number of Registered Trials

7.3.9.    Analysis by Trial Focus

7.3.10.  Analysis by Therapeutic Area

7.3.11.  Analysis by Clinical Endpoints

 

8.         ACADEMIC GRANTS ANALYSIS

8.1.       Chapter Overview

8.2.       Scope and Methodology

8.3.       Target Protein Degradation: Analysis of Academic Grants

8.3.1.    Analysis by Year of Grant Award

8.3.2.    Analysis by Amount Awarded

8.3.3.    Analysis by Funding Institute Center

8.3.4.    Analysis by Support Period

8.3.5.    Analysis by Funding Institute Center and Support Period

8.3.6.    Analysis by Type of Grant Application

8.3.7.    Analysis by Purpose of Grant Award

8.3.8.    Analysis by Activity Code

8.3.9.    Emerging Focus Areas (Word Cloud)

8.3.10.  Analysis by Study Section Involved

8.3.11.  Popular NIH Departments: Analysis by Number of Grants

8.3.12.  Analysis by Type of Recipient Organization

8.3.13.  Prominent Program Officers: Analysis by Number of Grants

8.3.14.  Popular Recipient Organizations: Analysis by Number of Grants

8.3.15.  Regional Distribution of Recipient Organizations

 

9.         PUBLICATION ANALYSIS

9.1.       Chapter Overview

9.2.       Scope and Methodology

9.3.       Targeted Protein Degradation-Based Therapeutics and Technologies: Recent Publications

9.3.1.    Analysis by Year of Publication

9.3.2.    Analysis by Study Objective

9.3.3.    Emerging Focus Areas

9.3.4.    Analysis by Type of Protein Degrader

9.3.5.    Analysis by Target Protein

9.3.6.    Analysis by Target Enzyme

9.3.7.    Analysis by Target Indication

9.3.8.    Analysis by Type of Publisher

9.3.9.    Leading Players: Analysis by Number of Publications

9.3.10.  Leading Players: Geographical Analysis by Number of Publications

9.3.11.  Key Journals: Analysis by Number of Publications

 

10.       PATENT ANALYSIS

10.1.     Chapter Overview

10.2.     Scope and Methodology

10.3.     Targeted Protein Degradation Technologies: Patent Analysis

10.3.1.  Analysis by Publication Year

10.3.2.  Analysis by Application Year

10.3.3.  Analysis by Geographical Location

10.3.4.  Analysis by CPC Symbols

10.3.5.  Emerging Focus Areas (Word Cloud)

10.3.6.  Analysis by Type of Organization

10.3.7.  Leading Players: Analysis by Number of Patents

10.4.     Target Protein Degradation Technologies: Benchmarking Patent Analysis

10.4.1.  Analysis by Patent Characteristics

10.5.     Target Protein Degradation-based Technologies: Patent Valuation Analysis

10.6.     Leading Patents by Number of Citations

 

11.       KOL ANALYSIS

11.1.     Chapter Overview

11.2.     Scope and Methodology

11.3.     Targeted Protein Degradation-based Therapeutics and Technologies: List of Principal Investigators

11.3.1.  Analysis by Designation

11.3.2.  Analysis by Phase of Development and Type of Protein Degrader

11.3.3.  Analysis by Therapeutic Area

11.3.4.  Analysis by Type of Organization

11.3.5.  Analysis by Location of Organization

11.3.6.  Leading Organizations: Analysis by Number of Affiliated Principal                                    Investigators

 

11.4.     Prominent Key Opinion Leaders (KOLs)

11.5.     KOL Benchmarking: Roots Analysis versus Third Party Scoring (ResearchGate Score)

11.6.     Profiles of Most Active KOLs

11.6.1.  Profile: KOL A (Barbara Ann Karmanos Cancer Center)

11.6.2.  Profile: KOL B (Celgene)

11.6.3.  Profile: KOL C (Feinberg School of Medicine, Northwestern University)

11.6.4.  Profile: KOL D (Royal Marsden NHS Foundation Trust)

11.6.5.  Profile: KOL E (Samus Therapeutics)

11.6.6.  Profile: KOL F (Stanford Women Cancer Center)

11.6.7.  Profile: KOL G (University of North Carolina at Chapel Hill)

11.6.8.  Profile: KOL H (University of Toledo)

 

12.       PARTNERSHIPS AND COLLABORATIONS

12.1.     Chapter Overview

12.2.     Partnership Models

12.3.     Targeted Protein Degradation-based Therapeutics and Technologies: Recent Partnerships and Collaborations

12.3.1.  Analysis by Year of Partnership

12.3.2.  Analysis by Type of Partnership

12.3.3.  Analysis by Type of Protein Degrader

12.3.4.  Analysis by Protein Degradation Technology

12.3.5.  Analysis by Therapeutic Area

12.3.6.  Most Active Players: Analysis by Number of Partnerships

12.3.7.  Geographical Analysis

12.3.7.1.           Most Active Players: Regional Analysis by Number of Partnerships

12.3.7.2.           Intercontinental and Intracontinental Agreements

 

13.       FUNDING AND INVESTMENT ANALYSIS

13.1.     Chapter Overview

13.2.     Types of Funding

13.3.     Targeted Protein Degradation-based Therapeutics and Technologies: Recent Funding Instances

13.3.1.  Analysis by Year of Investment

13.3.2.  Analysis by Amount Invested

13.3.3.  Analysis by Type of Funding

13.3.4.  Analysis by Amount Invested for Different Types of Degraders

13.3.5.  Analysis by Amount Invested across Different Therapeutic Areas

13.3.6.  Analysis by Amount Invested across Different Technology Platforms

13.3.7.  Most Active Players: Analysis by Number of Funding Instances and Amount Invested

13.3.8.  Most Active Investors: Analysis by Participation

13.3.9.  Geographical Analysis by Amount Invested

13.4.     Concluding Remarks

 

14.       MARKET SIZING AND OPPORTUNITY ANALYSIS

14.1.     Chapter Overview

14.2.     Assumptions and Methodology

14.3.     Targeted Protein Degradation-based Therapeutics and Technologies: Information on Licensing Deals

                       

14.4.     Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, 2021-2030

14.4.1.  Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader

14.4.1.1.           Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, 2021-2030

14.4.1.2.           Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, 2021-2030

14.4.1.3.           Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs / SERDs, 2021-2030

14.4.1.4.           Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, 2021-2030

14.4.1.5.           Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Inhibitors, 2021-2030

 

14.4.2.  Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area

14.4.2.1.           Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, 2021-2030

14.4.2.2.           Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, 2021-2030

14.4.2.3.           Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, 2021-2030

 

14.4.3.  Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration

14.4.3.1.           Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, 2021-2030

14.4.3.2.           Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, 2021-2030

14.4.3.3.           Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes of Administration, 2021-2030

 

14.4.4.  Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Geography

14.4.4.1.           Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, 2021-2030

14.4.4.2.           Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, 2021-2030

14.4.4.3.           Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, 2021-2030

14.4.5.  Targeted Protein Degradation-based Therapeutics and Technologies Market: Share of Key Contributing Technologies, 2021-2030

 

15.       LICENSING DEAL STRUCTURE

 

16.       EXECUTIVE INSIGHTS

16.1.     Chapter Overview

16.2.     Polyprox Therapeutics

16.2.1.  Company Snapshot

16.2.2.  Interview Transcript: Laura Itzhaki, Founder and Chief Scientific Officer

16.3.     Xios Therapeutics

16.3.1.  Company Snapshot

16.3.2.  Interview Transcript: Louise Bergeron, Vice President

16.4.     Almac

16.4.1.  Company Snapshot

16.4.2.  Interview Transcript: Martin Wiles, Vice President Business Development and Licensing & Gerald Gavory, Director of Biology

16.5.     Ubiquigent

16.5.1.  Company Snapshot

16.5.2.  Interview Transcript: Jason Brown, Scientific and Business Development Director

16.6.     Interview Transcript: Anonymous, Director of Oncology Research

16.7.     Interview Transcript: Anonymous, Chief Scientific Officer

16.8.     Francis Crick Institute

16.8.1.  Company Snapshot

16.8.2.  Interview Transcript: Katrin Rittinger, Research Group Leader

16.9.     University of Delaware

16.9.1.  Company Snapshot

16.9.2.  Interview Transcript: Zhihao Zhuang, Associate Professor, Department of Chemistry and Biochemistry

 

17.       CONCLUDING REMARKS

 

18.      APPENDIX 1: TABULATED DATA

 

19.      APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

0 Comments


Recommended Comments

There are no comments to display.

Guest
Add a comment...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
  • Create New...